Eckert & Ziegler SE (XTER:EUZ) Valuation Rank

View and export this data going back to 1999. Start your Free Trial

What is Eckert & Ziegler SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Eckert & Ziegler SE Valuation Rank Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (XTER:EUZ) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

1EUZ:Italy EUZd:UK 0NZY:UK

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, 13125

Website

https://www.ezag.com

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Executives

Dr. Andreas Eckert	Supervisory Board
Frank Perschmann	Supervisory Board
Dr. Hakim Bouterfa	Board of Directors
Prof. Dr. Wolfgang Maennig	Supervisory Board
Dr. Harald Hasselmann	Board of Directors